Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs Post author:Sam Post published:January 25, 2018 Post category:BioPharma The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace You Might Also Like As the IDO Battle Gets Ugly, Bristol-Myers Shows Off Early Data for Combo Trial November 9, 2017 True or False: Publishing Negative Results Ruins Your Science Career March 15, 2017 Bay Area???s Dynavax Shifts Focus to Immune-Oncology, Cuts 40% of Staff March 12, 2017
